Blazar B R, Taylor P A, Bluestone J A, Vallera D A
Department of Pediatrics, University of Minnesota Hospital, Minneapolis, USA.
Blood. 1996 May 15;87(10):4463-72.
T cells with antidonor specificities have been isolated from human recipients experiencing graft rejection after allogeneic bone marrow transplantation (BMT). Partial T-cell depletion of unrelated BM grafts with an anti- T-cell receptor (TCR) monoclonal antibody (MoAb) directed against the TCR alpha/beta heterodimer have shown that the incidence of graft-versus-host disease is low and that the incidence of durable engraftment is high. These studies suggest either that the number of residual TCR alpha/beta+ cells was sufficient to permit alloengraftment or that the preservation of cells other than TCR alpha/beta+ cells was beneficial for engraftment. With respect to the latter, one such candidate cell is the TCR gamma/delta+ T cell. Because no studies have specifically examined whether TCR gamma/delta+ cells might be capable of eliminating BM-derived hematopoietic cells, we established a new graft rejection model system in which transgenic (Tg) H-2d mice (termed G8), known to express gamma/delta heterodimers on high proportion of peripheral T cells, were used as BMT recipients. These Tg TCR gamma/delta+ cells respond vigorously to target cells that express the nonclassical major histocompatibility complex (MHC) class lb region gene products encoded in H-2T region of H-2T(b)+ strains. G8 Tg mice were used as recipients for C57BL/6 (B6: H-2(b); H-2T(b)) T-cell-depleted (TCD) donor BM. We show that G8 Tg (H-2(d), H-2T(d)) mice are potent mediators of B6 BM graft rejection and that the rejection process was inhibited by anti-TCR gamma/delta MoAbs. In contrast, BM from a B6 congenic strain that expresses the H-2T(a) allele, B6.A-Tl(a)/BoyEg, was readily accepted, suggesting that H-2T antigens on repopulating donor BM cells are the targets of host graft rejecting T cells that express the TCR gamma/delta heterodimer. PB chimerism studies were performed at > or = 1.5 months post-BMT using TCD BM from severe combined immunodeficient allogeneic donors, which is highly susceptible to rejection by the host. The addition of donor G8 TCR gamma/delta+ cells to TCD donor BM was shown to significantly increase alloengraftment in B6 recipients. These results show that (1) host TCR gamma/delta+ cells can reject repopulating donor cells, presumably by responding to nonclassical MHC class lb gene products expressed on BM-derived hematopoietic progenitor cells; and (2) donor TCR gamma/delta+ cells can facilitate the alloengraftment of rigorously TCD donor BM.
在接受异基因骨髓移植(BMT)后发生移植物排斥反应的人类受者中,已分离出具有抗供体特异性的T细胞。用针对T细胞受体(TCR)α/β异二聚体的抗T细胞受体单克隆抗体(MoAb)对无关供体骨髓移植物进行部分T细胞清除,结果显示移植物抗宿主病的发生率较低,而持久植入的发生率较高。这些研究表明,要么残余的TCRα/β+细胞数量足以允许同种异体植入,要么保留TCRα/β+细胞以外的细胞对植入有益。关于后者,一种这样的候选细胞是TCRγ/δ+ T细胞。由于尚无研究专门探讨TCRγ/δ+细胞是否能够清除骨髓来源的造血细胞,我们建立了一种新的移植物排斥模型系统,其中已知在外周T细胞高比例表达γ/δ异二聚体的转基因(Tg)H-2d小鼠(称为G8)被用作BMT受者。这些Tg TCRγ/δ+细胞对表达由H-2T(b)+品系的H-2T区域编码的非经典主要组织相容性复合体(MHC)I类b区基因产物的靶细胞有强烈反应。G8 Tg小鼠被用作C57BL/6(B6:H-2(b);H-2T(b))T细胞清除(TCD)供体骨髓的受者。我们发现G8 Tg(H-2(d),H-2T(d))小鼠是B6骨髓移植物排斥的有效介导者,并且排斥过程被抗TCRγ/δ MoAb抑制。相反,表达H-2T(a)等位基因的B6同源品系B6.A-Tl(a)/BoyEg的骨髓很容易被接受,这表明再植供体骨髓细胞上的H-2T抗原是表达TCRγ/δ异二聚体的宿主移植物排斥T细胞的靶标。在BMT后≥1.5个月,使用来自严重联合免疫缺陷同种异体供体的TCD骨髓进行外周血嵌合研究,该供体骨髓极易被宿主排斥。向TCD供体骨髓中添加供体G8 TCRγ/δ+细胞可显著增加B6受体中的同种异体植入。这些结果表明:(1)宿主TCRγ/δ+细胞可能通过对骨髓来源的造血祖细胞上表达的非经典MHC I类b基因产物作出反应来排斥再植供体细胞;(2)供体TCRγ/δ+细胞可促进经过严格TCD的供体骨髓的同种异体植入。